×

Innovus Pharma to Exhibit Zestra(R), Its Clinically Proven Topical Product for Sexual Arousal and Desire at the 46th Annual Meeting of the American Association of Sexuality Educators Counselors & Therapists

SAN DIEGO, June 4, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that it will exhibit Zestra®, its topical over-the-counter ("OTC") product for female sexual arousal and desire, at the 46th Annual Meeting of the American Association of Sexuality Educators Counselors & Therapists ("AASECT") in Monterrey, CA. The meeting will be held from June 4-8, with exhibits from June 6-7 at the Portola Hotel and Spa. Innovus will be presenting the clinical benefits and use of Zestra® at its booth during the exhibition with education sessions to sexual counselors, educators and therapists throughout the meeting.

"Sex therapists, counselors and educators play a major role in sexual desire and arousal disorder management for women," said Dr. Bassam Damaj, President and CEO of Innovus Pharma. "We are honored to be able to provide samples of Zestra® and discuss its clinical benefits to patients suffering from sexual arousal and desire disorders with such an important group of therapists."

Zestra® is the only OTC natural product clinically proven in two U.S. double-blind, placebo controlled trials in 276 women to increase arousal, desire and satisfaction during sexual intercourse. Zestra® is recommended by top therapists and gynecologists and is currently commercialized in the U.S. and Canada and has sold millions of units since its launch in 2007.

Zestra® is currently sold in close to 1,700 retail stores in the United States with Walmart being the largest retail chain with 1,400 of its superstores stores. In addition, Zestra® is available through wholesale drug distributors such as Cardinal Health and McKesson.

Founded in 1967, AASECT has over 2,000 members and is devoted to the promotion of sexual health by the development and advancement of the fields of sexual therapy, counseling, and education. AASECT's mission is the advancement of the highest standards of professional practice for educators, counselors and therapists.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra® for female arousal, and EjectDelay™ for premature ejaculation, and has a total of four marketed products in this space including CIRCUMSerum™ (for sales outside the U.S. only) and Zestra® Glide.

For more information, go to www.innovuspharma.com.

INNOVUS PHARMA'S FORWARD-LOOKING Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra®, to successfully commercialize such products, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

CONTACT: Innovus Pharma Contact: Kevin Holmes Chesapeake Group info@chesapeakegp.com T: 410-825-3930Source:Innovus Pharmaceuticals, Inc.